肯尼亚HIV-1感染青少年四价HPV疫苗第7和12个月免疫原性与免疫状态的相关性
在肯尼亚9-14岁HIV-1感染青少年中开展开放标签试验,按0、2、6月接种四价HPV疫苗,第7和12月检测HPV-16/18/6/11抗体。第7月血清阳转率93.3%-99.6%,与历史对照相似;CD4每升高1个log10,HPV抗体滴度升高0.7-1.4个log10。
要点
- HIV-1感染青少年接种qHPV后血清阳转率与历史对照相当。
- CD4细胞计数越高,HPV抗体滴度越高。
- 疫苗安全性良好,未发现疫苗相关严重不良事件。
核心结论
- 几乎所有肯尼亚HIV-1感染青少年均产生与其他免疫人群相当的免疫应答。
- CD4细胞计数保持较好的个体HPV抗体滴度更高。
研究设计与样本
- 开放标签试验,纳入肯尼亚9-14岁HIV-1感染青少年,按0、2、6月接种四价HPV疫苗。
- 共入组100名女孩和80名男孩,中位年龄12岁,中位基线CD4计数684(IQR 478, 935)cells/µL。
- 189名入组儿童中179名完成三剂接种,第7和12月检测HPV-16、18、6、11抗体滴度。
主要发现
- 第7月HPV-18、16、11、6血清阳转率分别为93.3%、98.3%、97.2%、99.6%,与历史对照相似。
- 第7月平均log10 HPV抗体滴度随CD4每升高1个log10而升高:HPV-18为1.4(95%CI 1.1-1.7),HPV-16为1.2(0.9-1.4),HPV-11为1.1(0.8-1.3),HPV-6为0.7(0.5-1.0),均p<0.0001。
临床怎么用
- HIV-1感染青少年可考虑接种四价HPV疫苗以预防HPV感染。
- 接种时关注CD4细胞计数,免疫状态较好者抗体应答更高。
局限性
- 需更长期随访以确定免疫应答的持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In sub-Saharan Africa, a generation of HIV-1-infected children is approaching the age of sexual debut and becoming at risk for HPV infection and its sequelae. We assessed safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine in HIV-1-infected adolescents. METHODS: In an open-label trial among Kenyan, HIV-1-infected adolescents aged 9-14 years, we administered the qHPV vaccine at 0, 2 and 6 months and measured antibody titers to HPV-16, 18, 6 and 11 at month 7 and 12 post-vaccination. Measures of immunogenic response from HIV-1-negative historical cohorts from Africa and HIV-1 positive adolescent cohorts from the USA were used for comparison. RESULTS: We enrolled 100 girls and 80 boys with a median age of 12 years and median baseline CD4 cell count of 684 (IQR 478, 935) cells/µL. One hundred and fifty four (86%) were receiving antiretroviral therapy for a median of 4.5 (IQR 2.3, 6.3) years; 110 (71%) had <400 copies of plasma HIV-1 RNA/mL. Of 189 enrolled children, 179 received all three doses. Two hundred and eighty five (64%) of 445 adverse events were injection site reactions; none were greater than grade 2. Of 6 Serious Adverse Events (SAEs), none were considered vaccine related. Seroconversion to HPV-18, 16, 11, 6 at month 7 occurred in 93.3%, 98.3%, 97.2% and 99.6% of vaccine recipients; similar rates have been reported in historical controls. The mean log10 HPV antibody titer measured at month 7 increased with each log10 increase in CD4 by 1.4 (95% CI: 1.1-1.7) for HPV-18; 1.2 (0.9-1.4) for HPV-16; 1.1 (0.8-1.3) for HPV-11; 0.7 (0.5-1.0) for HPV-6 (all p < 0.0001). CONCLUSION: Almost all Kenyan HIV-1-infected adolescents mounted an immune response comparable to other immunized populations. HPV antibody titers were higher in those with preserved CD4 cell counts. Longer term-follow up will determine sustainability of the immune response. ClinicalTrials.gov number, NCT00557245.
引用
- Mugo NR, Eckert L, Magaret AS, et al. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status. Vaccine. 2018. PMID: 30297124. doi:10.1016/j.vaccine.2018.09.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。